Histidine

Histidine

SCHEMBL7609568

N[C@@H](Cc1c[nH]cn1)C(=O)O.O=C(O)[C@@H]1CCCN1.O=C1CC[C@@H](C(=O)O)N1

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
TRHR P34981 2/20 0.33
ITGA4 P13612 4/20 0.32
ITGB1 P05556 2/20 0.32
GRIK1 P39086 1/20 0.30
GRIA1 P42261 1/20 0.30
GRIA2 P42262 1/20 0.30
GRIA3 P42263 1/20 0.30
GRIA4 P48058 1/20 0.30
GRIK2 Q13002 1/20 0.30
GRIK3 Q13003 1/20 0.30
GRIK4 Q16099 1/20 0.30
GRIK5 Q16478 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Histidine SCHEMBL6903283 0.95 TRHR (0.34) TRHRITGA4ITGB1
Histidine SCHEMBL2586203 0.91 SLC7A5 (0.35) GRIK1GRIA1GRIA2GRIA3GRIA4
D-Histidine SCHEMBL11606906 0.91 SLC7A5 (0.35) GRIK1GRIA1GRIA2GRIA3GRIA4
Histidine SCHEMBL2586200 0.91 SLC7A5 (0.35) GRIK1GRIA1GRIA2GRIA3GRIA4
Histidine SCHEMBL27902238 0.91 SLC7A5 (0.35) GRIK1GRIA1GRIA2GRIA3GRIA4
Histidine SCHEMBL16444321 0.89 CYP3A4 (0.32) GRIA1GRIA2GRIA3GRIA4
Histidine SCHEMBL10828038 0.87 CYP1A2 (0.33) ITGA4GRIK1GRIK2GRIK3GRIK4
Histidine SCHEMBL3088582 0.87 CYP3A4 (0.32)
Histidine SCHEMBL3490081 0.87 CYP3A4 (0.32)
Histidine SCHEMBL1675273 0.87 CYP3A4 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020177558-A1 METHOD OF TREATING, PREVENTING OR INHIBITING CENTRAL NERVOUS SYSTEM INJURIES AND DISEASES ARMY, UNITED STATES 2002-11-28 US disclosed
US-6469049-B1 Administering a lipoic acid compound, such as alpha-lipoic acid, dihydrolipoic acid, or 2-(N,N-dimethylamino)ethylamido lipoate-HCL. THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2002-10-22 US disclosed
WO-2001080851-A1 METHOD OF TREATING, PREVENTING OR INHIBITING CENTRAL NERVOUS SYSTEM INJURIES AND DISEASES UNITED STATES ARMY MEDICAL RESEARCH AND MATERIEL COMMAND (US) 2001-11-01 WO disclosed